Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023 ...Middle East

The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors The combination treatment produced an objective response rate (ORR ) of 52.4% in the advanced cervical...

Hence then, the article about antengene to present latest results from torch 2 study of atg 008 in advanced solid tumors in poster discussion at asco 2023 was published today ( Friday 26/05/2023 - 04:52 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023 )

Also on site :

• Large house fire near Buckeye Lake kills one, critically injures second victim
• 'Sister Wives' Meri Brown Opens Up About Family Finances After Consenting to ‘Never Talk’ About Kody Deal
• A Recent Tragedy Has Left My Kids Devastated. But I’m Secretly Pleased.